Interleukin 1 protects against 1-beta-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model.
Alopecia is one of the most psychologically distressing side effects of cancer chemotherapy. Previously, we made the following observations: (a) treatment of 8-day-old rats with 1-beta-D-arabinofuranosylcytosine (ara-C), doxorubicin, and cyclophosphamide (CYC) consistently produced either total body alopecia (ara-C and CYC) or alopecia confined to the head and proximal part of the neck (doxorubicin); (b) Imuvert, a biological response modifier derived from the bacterium Serratia marcescens, uniformly produced complete protection against alopecia induced by ara-C and doxorubicin but not that induced by CYC; and (c) the protective effect of Imuvert against chemotherapy-induced alopecia is mediated by a monocyte-mediated cytokine. In the experiments reported here, interleukin 1 was examined as the potential cytokine. Interleukin 1 offered excellent protection against alopecia induced by ara-C but not that produced by CYC in the newborn rat animal model.
Hussein
A M
AM
William J. Harrington Center for Blood Diseases, University of Miami School of Medicine, Florida 33136.
D000505:Alopecia / Q000139:chemically induced / Q000517:prevention & control*; D000818:Animals; D000831:Animals, Newborn; D003520:Cyclophosphamide / Q000633:toxicity; D003561:Cytarabine / Q000633:toxicity*; D006801:Humans; D007375:Interleukin-1 / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000627:therapeutic use
D007375:Interleukin-1; D011994:Recombinant Proteins; D003561:Cytarabine; D003520:Cyclophosphamide